XFOR FY2029 EPS Estimate Lifted by Brookline Capital Markets

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Capital Markets increased their FY2029 EPS estimates for shares of X4 Pharmaceuticals in a report issued on Wednesday, May 6th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of $0.88 for the year, up from their prior estimate of $0.85. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.87) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals’ FY2030 earnings at $2.93 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $3.20 million. X4 Pharmaceuticals had a negative return on equity of 118.77% and a negative net margin of 1,106.30%.

XFOR has been the topic of several other reports. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Guggenheim started coverage on X4 Pharmaceuticals in a research report on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.50.

X4 Pharmaceuticals Trading Up 1.4%

Shares of XFOR stock opened at $4.35 on Friday. X4 Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $4.83. The company has a quick ratio of 9.98, a current ratio of 10.16 and a debt-to-equity ratio of 0.41. The business has a fifty day simple moving average of $4.03 and a 200-day simple moving average of $3.82. The stock has a market cap of $395.50 million, a P/E ratio of -0.94 and a beta of 0.31.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after buying an additional 22,485 shares during the period. Rhumbline Advisers raised its stake in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the period. Jane Street Group LLC boosted its holdings in shares of X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after purchasing an additional 51,544 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock valued at $1,404,000 after purchasing an additional 178,593 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new position in X4 Pharmaceuticals in the 3rd quarter worth $326,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.